Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy for CLL shows promise in small japanese study

NCT ID NCT05105841

Completed Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed phase 2 study tested two drug combinations—venetoclax plus obinutuzumab or venetoclax plus ibrutinib—in 20 Japanese adults with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal was to see how well these combinations work and if they are safe. Participants received the drugs in 28-day cycles for up to 15 cycles, and doctors monitored their response and side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Venetoclax (Venclexta) combined with obinutuzumab (Gazyva) or ibrutinib (Imbruvica)
What this could lead to
If successful, this could show that these drug combinations are safe and effective for Japanese patients with CLL/SLL, potentially offering new treatment options.
What could go wrong
This is a small, early-phase study (20 participants) focused on Japanese patients, so results may not apply broadly. Side effects from the drug combinations are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) SMALL LYMPHOCYTIC LYMPHOMA (SLL)

Contacts and locations

Locations

  • Aichi Cancer Center Hospital /ID# 238797

    Nagoya, Aichi-ken, 464-8681, Japan

  • Duplicate_Chiba Cancer Center /ID# 238839

    Chiba, Chiba, 260-8717, Japan

  • Duplicate_Hokkaido University Hospital /ID# 238377

    Sapporo, Hokkaido, 060-8648, Japan

  • Duplicate_Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital /ID# 233524

    Nagoya, Aichi-ken, 466-8650, Japan

  • Duplicate_Jichi Medical University Hospital /ID# 238434

    Shimotsuke-shi, Tochigi, 329-0498, Japan

  • Duplicate_NHO Nagoya Medical Center /ID# 233523

    Nagoya, Aichi-ken, 460-0001, Japan

  • Duplicate_Okayama University Hospital /ID# 238467

    Okayama, Okayama-ken, 700-8558, Japan

  • Duplicate_Osaka University Hospital /ID# 234037

    Suita-shi, Osaka, 565-0871, Japan

  • Duplicate_Shimane University Hospital /ID# 234076

    Izumo-shi, Shimane, 693-8501, Japan

  • Hyogo Prefectural Amagasaki General Medical Center /ID# 234082

    Amagasaki-shi, Hyōgo, 660-8550, Japan

  • Kindai University Hospital /ID# 234001

    Osakasayama-shi, Osaka, 589-8511, Japan

  • Kyushu University Hospital /ID# 238437

    Fukuoka, Fukuoka, 812-8582, Japan

  • National Cancer Center Hospital /ID# 232449

    Chuo-ku, Tokyo, 104-0045, Japan

  • National Hospital Organization Shikoku Cancer Center /ID# 234059

    Matsuyama, Ehime, 791-0280, Japan

  • Niigata University Medical & Dental Hospital /ID# 238324

    Niigata, Niigata, 951-8520, Japan

  • The Cancer Institute Hospital Of JFCR /ID# 232450

    Koto-ku, Tokyo, 135-8550, Japan

  • Tohoku University Hospital /ID# 238433

    Sendai, Miyagi, 9808574, Japan

  • Tokai University Hospital /ID# 238970

    Isehara, Kanagawa, 259-1193, Japan

  • University Hospital Kyoto Prefectural University of Medicine /ID# 239883

    Kyoto, Kyoto, 602-8566, Japan

  • Yamagata University Hospital /ID# 234032

    Yamagata, Yamagata, 990-9585, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.